- Home
- PRLD vs DXR Comparison
PRLD vs DXR Comparison
Compare PRLD & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | DXR |
|---|---|---|
| Founded | 2016 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 61.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRLD | DXR |
|---|---|---|
| Price | $2.12 | $12.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 470.6K | 2.9K |
| Earning Date | 11-12-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $10,500,000.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.77 |
| Revenue Growth | ★ 250.00 | N/A |
| 52 Week Low | $0.61 | $6.55 |
| 52 Week High | $4.22 | $14.15 |
Technical Indicators
Market Signals| Indicator | PRLD | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 52.14 |
| Support Level | $1.60 | $12.38 |
| Resistance Level | $2.17 | $12.67 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 93.71 | 59.58 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.